Steve Lombardi has joined Helicos BioSciences as senior vice president of marketing.
Lombardi most recently served as a senior vice president at Affymetrix, where he was responsible for corporate development, product R&D and marketing, and corporate marketing between 2002 and 2006.
Prior to Affymetrix, Lombardi worked for 16 years at Applied Biosystems as a marketing manager and as an executive. From 1989 to 1998, Lombardi managed ABI's DNA sequencing and genetic analysis business.
David Gelfand has joined the scientific advisory board of Innovative Biosensors.
Gelfand most recently served as vice president of discovery research at Roche Molecular Systems. Prior to that, he was with Cetus, where he founded the company's recombinant molecular research division in 1976.
Affibody, GE Healthcare in Imaging Agent Research Collaboration
Affibody said this week that it has begun a research collaboration with GE Healthcare to develop imaging agents for applications in personalized medicine.
Affibody will provide its Affibody molecules for three disease targets defined by GE Healthcare. The Affibody molecules will be developed for targeted in vivo imaging applications, Affibody said.
GE Healthcare has the exclusive option to license the molecules for development and commercialization as imaging agents, while Affibody retains rights for use of the molecules outside the scope of in vivo diagnostic and medical imaging.
Invitrogen to Use BioProcessors' SimCell in Process Development Offering
Invitrogen said this week that it will add the SimCell robotic system from BioProcessors to its process development services offering.
Under the terms of the technology collaboration agreement, Invitrogen is installing a SimCell unit in its Grand Island, NY, facility.
Invitrogen's PD-Direct clients will have access to BioProcessors' high throughput simulated scale-down bioreactor tool beginning this fall. PD-Direct handles manufacturing scale-up, quality testing, and cell line optimization functions for biotechnology and pharmaceutical companies.
The companies will collaborate on the development of high-throughout cell culture applications for the SimCell platform and will expand microbioreactor technology for use in other areas, Invitrogen said.
Shimadzu, Phenomenome to Develop Biomarker Discovery Tools
Shimadzu and Phenomenome Discoveries have agreed to collaborate exclusively to develop tools for biomarker discovery and global profiling studies, including proteomic studies, the companies said this week.
A year ago, Shimadzu and Phenomenome inked a deal that allowed researchers to use Phenomenome's informatics platform to visualize and interpret mass spectrometry data generated by Shimadzu technology for metabolomics research.
The current agreement extends this previous agreement by further integrating mass spectrometry data generated on Shimadzu's LCMS-IT-TOF systems with Phenomenome's Profiler informatics platform, Shimadzu said.
"The collaboration with Phenomenome has been enhanced to take into account the growing need of researchers working in biomarker discovery and comparative proteomics studies to use high mass accuracy MSn data," said Kozo Shimazu, Shimadzu's deputy general manager in the analytical and measuring instrument division. "We believe that this collaboration ... helps deliver a unique and integrated solution to help find components of biological significance."
Harvard Bioscience Buys Reader and Washer Product Lines from Anthos
Harvard Bioscience has purchased assets for the microplate reader and washer product lines from Anthos Labtec Instruments GmbH, the company said today.
Anthos is a subsidiary of Beckman Coulter. Harvard Bioscience completed the purchase through its Austrian subsidiary, Asys Hitech GmbH.
The acquisition strengthens Harvard Bioscience's own microplate reader and washer product line and expands the company's distribution channels. These product lines are expected to add $2 million to $3 million in revenue, said Chane Graziano, the company's chief executive officer, in a statement.
It also gives Asys Hitech a new design platform, software and a luminescence capability, said David Parr, managing director of Biochrom, Asys Hitech's parent company.
Asys will manufacture, develop and support products in its Salzburg, Austria facility.
Beckman Coulter sold the product lines to Asys after determining they were "not a good strategic fit" to its business, according to Chris Neary, a vice president of the company.
Terms of the sale were not disclosed.
Harvard Bio is still seeking a buyer for its capital equipment business, which it put on the block last August (see BioCommerce Week 8/4/2005).